Shares of Elevance Health Inc. ELV slid 1.24% to $391.22 Tuesday, on what proved to be an all-around positive trading session ...

Cantor Fitzgerald reaffirmed its Neutral stance on Humana (NYSE:HUM) stock, maintaining the price target at $290.00. The stock, currently trading at $257.34, has experienced a significant 11.4% ...

it is easy to disregard Elevance Health (NYSE:ELV). However, stock prices are usually driven by a company’s financial performance over the long term, which in this case looks quite promising.

With earnings season in full swing, the volume of insider transactions has fallen to seasonal lows, with only 615 transactions meeting the criteria for inclusion in Vickers Weekly Insider Report ...

We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click ...

Elevance Health (NYSE:ELV – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a ...

Wells Fargo & Company reduced their target price on shares of Elevance Health from $593.00 to $495.00 and set an “overweight” rating on the stock in a report on Monday, November 4th.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a high estimate of $512.00 and a low estimate of $478.00. A decline of 6.69% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

With its stock down 7.4% over the past three months, it is easy to disregard Elevance Health (NYSE:ELV). However, stock prices are usually driven by a company’s financial performance over the long ...

Price Targets: Gaining insights, analysts provide estimates for the future value of Elevance Health's stock. This comparison reveals trends in analysts' expectations over time. Analyzing these ...